ResearcherUniversity Hospital BonnActive in the last 2 years

Christian Möhring

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7651-4401; OpenAlex author ID A5025800680. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity … Co-author DOI 10.3390/jcm13133717 ↗
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. Co-author DOI 10.21037/jgo-22-632 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tim R. Glowka · 2 shared papers, 2023–2024 · strength 0.32
- Paper Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experi… DOI 10.21037/jgo-22-632 ↗
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Milka Marinova · 2 shared papers, 2023–2024 · strength 0.32
- Paper Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experi… DOI 10.21037/jgo-22-632 ↗
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Georg Feldmann · 2 shared papers, 2023–2024 · strength 0.32
- Paper Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experi… DOI 10.21037/jgo-22-632 ↗
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Maria Angeles Gonzalez-Carmona · 2 shared papers, 2023–2024 · strength 0.32
- Paper Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experi… DOI 10.21037/jgo-22-632 ↗
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Ingo G.H. Schmidt‐Wolf · 1 shared paper, 2024 · strength 0.15
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Marcus O. Thudium · 1 shared paper, 2024 · strength 0.15
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗
Holger M. Strunk · 1 shared paper, 2024 · strength 0.15
- Paper Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local … DOI 10.3390/jcm13133717 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.